Taking the Stage: Scientific Conferences

Friday, December 10, 2021
Diagnosis and Treatment of MF and PV: Where Are We and Where Are We Going?
Time: 11 AM - 2 PM
Location: Centennial 1 (Hyatt Regency Atlanta)
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:  Bone Marrow Failure Syndromes, Diseases
Laura C. Michaelis, MD, The Medical College of Wisconsin Inc., Lindsey Lyle, MS, PA-C, University of Colorado, Andrew T. Kuykendall, MD, H. Lee Moffitt Cancer Center & Research Institute and Abdulraheem Yacoub, MD, University of Kansas Cancer Center

Saturday, December 11, 2021
1020 Neutrophil Extracellular Traps (NETs) Contribute to the Formation of Microvascular Thrombosis in Immune Thrombotic Thrombocytopenic Purpura
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster I
1020 Neutrophil Extracellular Traps (NETs) Contribute to the Formation of Microvascular Thrombosis in Immune Thrombotic Thrombocytopenic Purpura
Noritaka Yada, Jingrui Sui, M.D., Ph.D., Liang Zheng, Ph.D. and X. Long Zheng, MD

1268 Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Vinod A. Pullarkat, MD, Mark Levis, MD, Gabriel N. Mannis, MD, Stephen A Strickland, Tara L. Lin, MD, Stefan Faderl, Divya Chakravarthy, Vijayalakshmi Chandrasekaran, Ronald S. Cheung and Harry P. Erba

1277 Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Elie Traer, MD, PhD, Ying Huang, MS, MA, Alice S. Mims, MD, Eytan M. Stein, MD, Maria R. Baer, MD, Wendy Stock, MD, Tibor Kovacsovics, MD, William Blum, MD, Martha L. Arellano, MD, Gary J. Schiller, MD, Rebecca L. Olin, MD, James M. Foran, MD, Mark R. Litzow, MD, Tara L. Lin, MD, Prapti Patel, MD, Matthew C. Foster, MD, Robert L. Redner, MD, Zeina Al-Mansour, MD, Christopher R. Cogle, MD, Michael M. Boyiadzis, MD, Ronan Swords, MD PhD, Robert H. Collins, MD, Jo-Anne Vergilio, M.D., Nyla A. Heerema, PhD, Leonard Rosenberg, PhD RPh, Ashley O. Yocum, PhD, Sonja Marcus, MPH, Timothy Chen, PhD, Franchesca Druggan, MSc, Mona Stefanos, MBChB, Theophilus J Gana, MD PhD, Abigail B. Shoben, PhD, Brian J. Druker, Amy Burd, PhD, John C. Byrd, MD, Ross L. Levine, MD and Uma Borate, MD

1279 Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Vu H. Duong, MD, Amy S. Ruppert, PhD, Alice S. Mims, MD, Uma Borate, MD, Eytan M. Stein, MD, Maria R. Baer, MD, Wendy Stock, MD, Tibor Kovacsovics, MD, William G. Blum, MD, Martha L. Arellano, MD, Gary J. Schiller, MD, Rebecca L. Olin, MD, MS, James M. Foran, MD, Mark R. Litzow, MD, Tara L. Lin, MD, Prapti A. Patel, MD, Matthew C. Foster, MD, Robert L. Redner, MD, Zeina Al-Mansour, MD, Christopher R. Cogle, MD, Ronan T. Swords, MD, Robert H. Collins, MD, Jo-Anne Vergilio, MD, Nyla A. Heerema, PhD, Leonard Rosenberg, PhD RPh, Ashley O. Yocum, PhD, Sonja Marcus, MPH2, Timothy Chen, PhD, Franchesca Druggan, MSc, Mona Stefanos, MBChB, Theophilus J Gana, MD PhD2, Abigail B. Shoben, PhD, Brian J. Druker, Amy Burd, PhD, John C. Byrd, MD, Ross L. Levine, MD and Michael M. Boyiadzis, MD

1281 Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with High-Risk and Relapsed/Refractory Acute Myeloid Leukemia (AML)
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I
Maro Ohanian, DO, Tara L. Lin, MD, Ellen Ritchie, MD, Michael Craig, MD, Apurv Agrawal, MD, Kathleen G. Halka, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Miranda Lim, BSN, Sherry A. Pierce, BSN, BA, Ana Tari Ashizawa, PhD, Hagop Kantarjian, MD, Jorge E. Cortes, MD and Gail J. Roboz, MD

131 Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study
Time: 1 PM
Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Evolution of Immunotherapeutic Regimens in B-cell Lymphomas
Catherine Thieblemont, MD, PhD, Michael Dickinson, MBBS, Joaquin Martinez-Lopez, MD, PhD, Arne Kolstad, MD, PhD, Jason P Butler, MBBS, MMedSc, Monalisa Ghosh, MD, Leslie L. Popplewell, MD, FACP, Julio C. Chavez, MD, MS, Emmanuel Bachy, MD, PhD, Koji Kato, MD, PhD, Hideo Harigae, MD, PhD, Marie Jose Kersten, MD, PhD, Charalambos Andreadis, MD, MSCE, Peter A. Riedell, MD, P. Joy Ho, MBBS, Jose Pérez-Simón, MD, Andy Chen, MD, PhD, Loretta Nastoupil, MD, Bastian Von Tresckow, MD, Andres JM Ferreri, MD, Takanori Teshima, Piers EM Patten, MB, ChB, FRCP, FRCPath, PhD, Joseph P. McGuirk, DO, Andreas Petzer, MD, Fritz Offner, MD, PhD, Andreas Viardot, MD, Pier Luigi Zinzani, MD, PhD, Ram Malladi, MD, Aiesha Zia, C Lobetti Bodoni, MD, PhD, Aisha Masood, MD, Stephen J. Schuster, MD, Nathan H. Fowler, MD and Martin H. Dreyling, MD, PhD

1373 Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Poster I
Aung M Tun, MD, Yucai Wang, MD, Aasiya Matin, David J. Inwards, MD, Patrick B. Johnston, M.D., Ph.D., Ivana N. Micallef, MD, Luis F. Porrata, MD, Jose C. Villasboas, MD, Jonas Paludo, MD, Han W. Tun, MD, Allison C. Rosenthal, DO, James R. Cerhan, MD, PhD, Thomas M. Habermann, MD, Thomas E. Witzig, MD, Grzegorz S. Nowakowski, MD and Stephen M. Ansell, MD, PhD

139 A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Advanced Myelofibrosis Clinically Relevant Abstract
Time: 12 PM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis
Harinder Gill, MBBS, MD, FRCP, FRCPath, Abdulraheem Yacoub, MD, Kristen M. Pettit, MD, Terrence Bradley, MD, Aaron T. Gerds, MD, MS, Maciej Tatarczuch, BMBS, Jake Shortt, FRACP, FRCPA, PhD, Natasha Joan Curtin, MD, FRACP, FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Adam J. Mead, MBBChir, Joachim R. Göthert, MD, Steffen Koschmieder, MD, Amber Jones, MA, Jennifer Peppe, BS1, Georges Natsoulis, Ph.D., Wan-Jen Hong, MD, William S. Stevenson, MBBS, PhD, Joanne Ewing, MD, PhD, Claire N. Harrison, DM, Alessandro Vannucchi, MD, Justin Watts, MD, David M Ross, MBBS, PhD, FRACP, FRCPA, Moshe Talpaz, MD and Hugh Young Rienhoff Jr., MD

140 A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy
Time: 12:15 PM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis
Abdulraheem Yacoub, MD, Mrinal M. Patnaik, MBBS, Haris Ali, MD, Eunice S. Wang, MD, Vikas Gupta, MD, FRCP, FRCPath, Sangmin Lee, MD, Gary J. Schiller, MD, Minakshi S. Taparia, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Srdan Verstovsek, MD, PhD, Joseph D. Khoury, Christopher L Brooks, PhD, Tariq I. Mughal, MD, FRCP and Naveen Pemmaraju, MD

142 Treatment of Myelofibrosis Patients with the TGF-β 1/3 Inhibitor AVID200 (MPN-RC 118) Induces a Profound Effect on Platelet Production
Time: 12:45 PM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis
John Mascarenhas, MD, Heidi E. Kosiorek, MS, Rupali Bhave, MD, Jeanne M. Palmer, MD, Andrew T. Kuykendall, MD, Ruben A. Mesa, MD, FACP, Raajit Rampal, MD, PhD, Aaron T. Gerds, MD, MS, Abdulraheem Yacoub, MD, Kristen M. Pettit, MD, Moshe Talpaz, MD, Rami S. Komrokji, MD, Marina Kremyanskaya, MD, PhD, Agapito Gonzalez, Frank Fabris, Lonette Sandy, Kathryn Johnson, Mikaela Doughtery, Erin McGovern, BA, Juan Arango Ossa, Dylan Domenico, Noushin Farnoud, PhD, Anna Rita Migliaccio, PhD, Mohamed E Salama, MD, Rona Singer Weinberg, PhD, Amy Kong, Vesna Najfeld, PhD, Carolyn Mead-Harvey, MS, Amylou C. Dueck, PhD, Lilian Varricchio, PhD and Ronald Hoffman, MD

1502 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Add-on Parsaclisib in Patients with Myelofibrosis Who Have Suboptimal Response to Ruxolitinib 
Time: 12:45 PM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I
Abdulraheem Yacoub, MD, Thamer Sliwa, MD, Hideto Tamura, MD, PhD, Michael Stouffs, PhD, Feng Zhou, PhD and Albert Assad, MD

240 European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database
Time: 12:45 PM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Risk Stratification and Prognostication
Douglas Tremblay, MD, Andrew Srisuwananukorn, MD, Lukas Ronner, MD, Nikolai Podoltsev, MD, PhD, Jason Gotlib, MD, MS, Mark L. Heaney, MD, Andrew T. Kuykendall, MD, Casey L. O'Connell, MD, Jamile M. Shammo, MD8, Angela Fleischman, MD, PhD, Ruben A. Mesa, MD, FACP, Abdulraheem Yacoub, MD, Ronald Hoffman, MD, Erin Moshier, MS, Nicole Zubizarreta and John Mascarenhas, MD

140 A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy 
Time: 12:15 PM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis
Abdulraheem Yacoub, MD, Mrinal M. Patnaik, MBBS, Haris Ali, MD, Eunice S. Wang, MD, Vikas Gupta, MD, FRCP, FRCPath, Sangmin Lee, MD, Gary J. Schiller, MD, Minakshi S. Taparia, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Srdan Verstovsek, MD, PhD, Joseph D. Khoury, Christopher L Brooks, PhD, Tariq I. Mughal, MD, FRCP and Naveen Pemmaraju, MD

65 Lenalidomide and Eltrombopag for Treatment in Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Study Combination Clinical Trial
Time: 10:30 AM
Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Low Risk Myelodysplastic Syndrome Prognosis and Treatment
Jesus D Gonzalez-Lugo, MD, Suman Kambhampati, MD, Abdulraheem Yacoub, MD, William Donnellan, Prafulla Bhagat, BSc, MSc, Karen Fehn, RN, BSN, Cassady Remy, PA-C, Sakshi Jasra, MD, Mohammad Kazemi, MD, Ioannis Mantzaris, MD, MS, R. Alejandro Sica, MD, Lizamarie Bachier-Rodriguez, MD, Mendel Goldfinger, MD, Noah Kornblum, MD, Kira Gritsman, MD, PhD, Ira Braunschweig, MD, Ulrich G. Steidl, MD/PhD, Britta Will, PhD, Aditi Shastri, MD and Amit Verma, MD

1642 Belantamab in Combination with Dexamethasone in Patients with Triple-Class Relapsed/Refractory Multiple Myeloma
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster I
Tahani Atieh, DO, Shebli Atrash, MD, Meera Mohan, MD, MS, Leyla Shune, MD, Zahra Mahmoudjafari, PhD, Julie Quick, Justin Riffel, Joseph P. McGuirk, DO, Ghulam Rehman Mohyuddin, MD, Al-Ola Abdallah, MD, Nausheen Ahmed, MD, Wei Cui and Anne Wishna

1654 An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I
Sumit Madan, MD, Al-Ola Abdallah, MD, Andrew J. Cowan, MD, William I. Bensinger, MD, Jens Hillengass, MD, PhD, Xavier Leleu, MD, Eva Medvedova, MD, Caitlin Costello, MD, Brea Lipe, MD, Henning Schade, MD, Rajneesh Nath, MD and Liping Laura Sun, PhD

162 Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial
Time: 1:15 PM
Program: Oral and Poster Abstracts
Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Novel Targets and Amyloid
Sagar Lonial, MD, FACP, Rakesh Popat, MBBS, FRCPath, PhD, Cyrille Hulin, Sundar Jagannath, MD, Albert Oriol, Paul G. Richardson, MD, Thierry Facon, Katja Weisel, Jeremy T. Larsen, Monique C. Minnema, MD, Al-Ola Abdallah, MD, Ashraf Z. Badros, MD, Stefan Knop, Edward A. Stadtmauer, Min Chen, Tuong Vi Nguyen, Alpesh Amin, Elisabeth Kueenburg, Teresa Peluso and Niels W.C.J. van de Donk

1760 Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Viral Infections Post-HCT: Results from an Open-Label Cohort of a Phase 2 Trial
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Clinical: Poster I
Sanjeet S Dadwal, MD, Michael Shuster, MD, Gary Douglas Myers, MD, Keith Boundy, MD, Marshelle Warren, MD, Elizabeth Stoner, MD, Thuy Truong, PhD and Joshua A. Hill, MD

1791 Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I
Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Stuart Seropian, MD, Hannah Choe, MD, Mark R. Litzow, MD, Nebu V. Koshy, Patrick Stiff, MD, Camille Abboud Sr., MD, Benjamin Tomlinson, MD, Sunil Abhyankar, MD, Parameswaran Hari, Zaid S. Al-Kadhimi, MD, George L. Chen, MD, Mitchell Sabloff, MSc, MD, FRCPC, Johnnie J. Orozco, MD, PhD, James M. Foran, MD, Partow Kebriaei, MD, Katarzyna Joanna Jamieson, MD, Margarida Magalhaes Magalhaes-Silverman, Koen van Besien, MD, PhD, Michael W. Schuster, MD, Arjun Law, MD, Moshe Levy, MD, Hillard M Lazarus, MD, Sergio A Giralt, MD, Mark S. Berger, MD, Jennifer A Spross, MA, Avinash G Desai, MD, Vijay Reddy, MD, PhD and John M. Pagel, MD, PhD

98 Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Prevention of graft vs. host disease after allogeneic hematopoietic cell transplantation
Rasmus T. Hoeg, MD, Anna Moroz, MD, PhD, Arpita Gandhi, MD, Lori Muffly, MD, MS, Parveen Shiraz, MD, Caspian Oliai, MD, Rohtesh S. Mehta, MD, MPH, MS, Samer A Srour, Joseph P. McGuirk, DO, Edmund K. Waller, PhD, MD, Sally Arai, MD, MS, Laura J. Johnston, MD, Robert Lowsky, MD, Andrew R. Rezvani, MD, Wen-Kai Weng, MD, PhD, David B. Miklos, MD, PhD, Matthew J. Frank, MD, PhD, John Tamaresis, Ying Lu, PhD1, Vaibhav Agrawal, Nathaniel B Fernhoff, PhD, Gerhard Bauer, Amy Putnam, J Scott McClellan, MD, PhD, Bronwen E. Shaw, MD, PhD, Mehrdad Abedi, MD, Robert S. Negrin, MD and Everett H Meyer, MD, PhD

1847 Outcomes with Natural Killer Cells Infusion after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Muhammad Umair Mushtaq, MD, Moazzam Shahzad, MD, Amna Y Shah, MD, Muhammad Usman Zafar, MD, Ezza Tariq, MBBS, Anam Hamid, Ayna Serwat, Iqra Anwar, MBBS, Sibgha Gull Chaudhary, MD, Nausheen Ahmed, MBBS, Sunil Abhyankar, MD, Natalie S. Callander, MD, Peiman Hematti, MD and Joseph P. McGuirk, DO

1848 Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Muhammad Umair Mushtaq, MD, Moazzam Shahzad, MD, Muhammad Usman Zafar, MD, Muhammad Arslan, MD, Ezza Tariq, MBBS, Naira Fatima, MBBS, Syeda Sadia Bokhari, MD, Javeria Shahani, Iqra Anwar, MBBS, Sibgha Gull Chaudhary, MD, Anurag K. Singh, MD, Sunil Abhyankar, MD, Natalie S. Callander, MD, Peiman Hematti, MD and Joseph P. McGuirk, DO

266 An In Vivo CRISPR Screening Platform to Identify New Therapeutic Targets in AML
Time: 2:15 PM
Program: Oral and Poster Abstracts
Session: 802. Chemical Biology and Experimental Therapeutics
Shan Lin, PhD, Clement Larrue, Nastassja K. Scheidegger, Bo Kyung A. Seong, Neekesh V Dharia, MD, PhD, Caroline Wechsler, Guillaume Kugener, Amanda L Robinchaud, Amy Conway, Biniam Adane, Scott Younger, PhD, Federica Piccioni, PhD, Lynn Lee, Mark Wunderlich, MS, Jerome Tamburini and Kimberly Stegmaier, MD

1899 Prospective Study to Reduce Clostridium Difficile Infection in Patients Receiving Autologous Stem Cell Transplantation
Time: 5:30 - 7:30 PM
Program: Oral and Poster Abstracts
Session: 901. Health Services Research—Non-Malignant Conditions: Poster I
Samuel David Maldonado Jr., MD, PhD, Joseph Van Galen, MD, Kyle Grose, PharmD, Michael Keng, MD and Leonid Volodin, MD

Sunday, December 12, 2021
2 Primary Analysis of ZUMA‑7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard‑of‑Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma 
Time: 2 - 4 PM
Program: General Sessions
Session: Plenary Scientific Session
Frederick L. Locke, MD, David B. Miklos, MD, PhD, Caron Jacobson, MD, Miguel-Angel Perales, MD, Marie José Kersten, MD, PhD, Olalekan O. Oluwole, MBBS, MPH, Armin Ghobadi, MD, Aaron P. Rapoport, MD, Joseph P. McGuirk, DO, John M. Pagel, MD, PhD, Javier Muñoz, MD, MS, MBA, FACP, Umar Farooq, MD, Tom Van Meerten, MD, PhD, Patrick M. Reagan, MD, Anna Sureda, Ian W. Flinn, MD, PhD, Peter Vandenberghe, MD, PhD, Kevin Song, MD, FRCPC, Michael Dickinson, MBBS, Monique C. Minnema, MD, Peter A. Riedell, MD, Lori A. Leslie, MD, Sridhar Chaganti, MD, Yin Yang, MS, MD, Simone Filosto, PhD, Marco Schupp, MD, Christina To, MD, Paul Cheng, MD, PhD, Leo I. Gordon, MD and Jason R. Westin, MD, MS, FACP

2203 Single-Cell Multiomics Reveals Increased Plasticity, Resistant Populations and Stem-Cell-like Blasts in KMT2A-Rearranged Leukemia
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 602. Disordered Gene Expression and Epigenetics in Hematologic Malignancies: Basic: Poster II
Changya Chen, Wenbao Yu, Fatemeh Alikarami, Qi Qiu, Chia-hui Chen, Jennifer Flournoy, Peng Gao, Yasin Uzun, Li Fang, Yuxuan Hu, Qin Zhu, Kai Wang, Clara Libbrecht, Alex Felmeister, Isaiah Rozich, Yang-yang Ding, Stephen P Hunger, Hao Wu, Patrick A. Brown, MD, Erin Guest, MD, David M Barrett, Kathrin M. Bernt, MD and Kai Tan, PhD

2296 Incidence and Characteristics of Central Nervous System Involvement in Adult Acute Myeloid Leukemia Patients
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 613. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II
Joshua Tatarian, Heather J Male, MD, MBA, Kenneth P Byrd, DO and Tara L. Lin, MD

2316 Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
Geoffrey L. Uy, MD, Vinod A. Pullarkat, MD, Praneeth Baratam, Robert K. Stuart, Stefan Faderl, Vijayalakshmi Chandrasekaran, Qi Wang, Divya Chakravarthy, Ronald S. Cheung and Tara L. Lin, MD

2318 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies Clinically Relevant Abstract
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
Naveen Pemmaraju, MD, Hagop Kantarjian, MD, Kendra Sweet, MD, Eunice S. Wang, MD, Andrew A. Lane, MD, PhD, Haris Ali, MD, Anthony S. Stein, MD, Abdulraheem Yacoub, MD, David A. Rizzieri, MD, Sumithira Vasu, MBBS, Vikas Gupta, MD, FRCP, FRCPath, Sangmin Lee, MD, Gary J. Schiller, MD, James M. Foran, MD, Minakshi S. Taparia, MBBS, Todd L. Rosenblat, MD, MS, Roland B. Walter, MD, Debra Sieminski, MS, PA-C, Madhu Anant, PhD, Mrinal M. Patnaik, MBBS, Tariq I. Mughal, MD, FRCP and Marina Konopleva, MD, PhD

2316 Phase 1b Study of Lower-Dose CPX-351 Plus Venetoclax As First-Line Treatment for Patients with AML Who Are Unfit for Intensive Chemotherapy: Preliminary Safety and Efficacy Results
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
Geoffrey L. Uy, MD, Vinod A. Pullarkat, MD, Praneeth Baratam, Robert K. Stuart, Stefan Faderl, Vijayalakshmi Chandrasekaran, Qi Wang, Divya Chakravarthy, Ronald S. Cheung and Tara L. Lin, MD

2356 ETS Family Transcription Factor Fusions in Childhood AML: Distinct Expression Networks and Clinical Implications
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
Jenny L. Smith, MSc, MEd, Rhonda E. Ries, MA, Yi-Cheng Wang, MS, Amanda R. Leonti, MS, Todd A. Alonzo, PhD, Alan S. Gamis, MD, MPH, Richard Aplenc, MD, PhD, Anders E. Kolb, MD, Benjamin J. Huang, MD, Xiaotu Ma, PhD, Timothy I. Shaw, PhD and Soheil Meshinchi, M.D., Ph.D.

2360 Impact of Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission and Additional Cytogenetic Aberrations at Diagnosis on Prognosis in 1256 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia: A Retrospective Study By the I-BFM-SG
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
Romy E. Van Weelderen, Kim Klein, MD, PhD, Christine J. Harrison, PhD, FRCPath, Hester A. De Groot-Kruseman, PhD, Jonas Abrahamsson, MD, PhD, Nira Arad-Cohen, MD, PhD, Emmanuelle Bart-Delabesse, PharmD, PhD, Barbara Buldini, MD, PhD, Barbara De Moerloose, Michael Dworzak, MD, PhD, Sarah Elitzur, MD, José M. Fernández Navarro, MD, Marta Fiocco, MSc, PhD, Robert B. Gerbing, MA, Bianca F. Goemans, MD, PhD, Erin Guest, MD, Shau-Yin Ha, MD, PhD, Henrik Hasle, MD, PhD, Kathy Jackson, MD, PhD, Charikleia Kelaidi, MD20*, Hélène Lapillonne, MD, PhD, Guy Leverger, MD, PhD, Franco Locatelli, MD, PhD, Takako Miyamura, MD, PhD, Sophia Polychronopoulou, MD, PhD, Mareike Rasche, MD, Jeffrey E. Rubnitz, MD, Jan Stary, Prof., MD, PhD, Daisuke Tomizawa, MD, PhD, Femke Verwer1, C. Michel Zwaan, Prof, MD, PhD and Gertjan J.L. Kaspers, Prof. MD, PhD

519 Significant Improvements in Survival for Patients with t(6;9)(p23;q34)/DEK-NUP214 in Contemporary Trials with Intensification of Therapy: A Report from the Children’s Oncology Group
Time: 5 PM
Program: Oral and Poster Abstracts
Session: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis
Katherine Tarlock, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Yi-Cheng Wang, MS, Rhonda E. Ries, MA, Betsy A Hirsch, PhD, Beverly Lange, MD, William G. Woods, MD, Todd M. Cooper, DO, Alan S. Gamis, MD, MPH, Jessica A. Pollard, MD, Richard Aplenc, MD, PhD, Anders E. Kolb, MD and Soheil Meshinchi, M.D., Ph.D.

2424 A First-in-Human Phase 1 Study of Oral LOXO-338, a Selective BCL2 Inhibitor, in Patients with Advanced Hematologic Malignancies (Trial in Progress)
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II
Alvaro J. Alencar, MD, Lindsey E. Roeker, MD, MSCE, Marc Hoffmann, MD, Guru Subramanian Guru Murthy, MD, Vishalkumar Patel, Nora C. Ku, MD, James M. Pauff, MD, PhD, Toby A. Eyre, Wojciech Jurczak, MD, PhD and Steven Le Gouill

523 Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit 
Time: 4:30 PM
Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphomas Prospective Therapeutic Trials: Novel Agents and Combinations
Jeremy S. Abramson, MD, Amy S. Ruppert, PhD, Sharmila Giri, MS, Ann Hudson, Eric D. Hsi, MD, Richard F. Little, MD, MPH, Steven D. Gore, MD, Anusha Vallurupalli, MD, Daniel J Landsburg, MD, Brad S. Kahl, MD, Jonathan W. Friedberg, MD, Nancy L. Bartlett, MD and John P. Leonard, MD

2512 A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II
Peter A. Riedell, MD, Jamie Brower, MS, Loretta Nastoupil, MD, Miguel-Angel Perales, MD4 Richard T. Maziarz, MD, Joseph P. McGuirk, DO, Veronika Bachanova, MD, PhD, Wei-Ting Hwang, PhD, Stephen J. Schuster, MD, Michael R. Bishop, MD and David L. Porter, MD

388 Rusfertide (PTG-300) Controls Hematocrit Levels and Essentially Eliminates Phlebotomy Requirement in Polycythemia Vera Patients 
Time: 10:15 AM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Novel Therapies for MPNs and JAK inhibitors for Myelofibrosis
Ronald Hoffman, MD, Marina Kremyanskaya, MD, PhD, Yelena Ginzburg, MD, Andrew T. Kuykendall, MD, Naveen Pemmaraju, MD, Abdulraheem Yacoub, MD, Jay Yang, MD, Suneel Gupta, Frank Valone, MD, Sarita Khanna, PhD and Srdan Verstovsek, MD, PhD

389 Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial 
Time: 10:30 AM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Novel Therapies for MPNs and JAK inhibitors for Myelofibrosis
Vikas Gupta, MD, FRCP, FRCPath, Abdulraheem Yacoub, MD, Srdan Verstovsek, MD, PhD, Ruben A. Mesa, MD, FACP, Claire N. Harrison, DM, Giovanni Barosi, MD, Jean-Jacques Kiladjian, MD, PhD, H. Joachim Deeg, MD, Salman Fazal, MD, Lynda Foltz, MD, FRCPC, Ryan J. Mattison, MD, Carole B. Miller, MD, Vinod Parameswaran, MD, Vishwanath Gharpure, MD MRCP FACP, Christopher Hernandez, MSc, Tianhua Wang, PhD and Moshe Talpaz, MD

2579 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment–Naive Myelofibrosis 
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
Abdulraheem Yacoub, MD, Thamer Sliwa, MD, Rosa Ayala, MD, PhD, Roberto Ferro, MD, Abdul Hai Mansoor, MD, Sue Erickson-Viitanen, PhD, Feng Zhou, PhD and Albert Assad, MD

2583 Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily Available Baseline Characteristics Clinically Relevant Abstract
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II
Andrew Srisuwananukorn, MD, Beth Percha, PhD, Ghaith Abu-Zeinah, MD, Joseph Scandura, MD, PhD, Spencer Krichevsky, MS, Elwood Taylor III, BS, Richard T. Silver, MD, Santiago Thibaud, MD, Lukas Ronner, MD, Nikolai Podoltsev, MD, PhD, Jason Gotlib, MD, MS, Mark L. Heaney, MD, Andrew T. Kuykendall, MD, Casey O’Connell, MD, Jamile M. Shammo, MD, Angela Fleischman, MD, PhD, Ruben A. Mesa, MD, FACP13, Abdulraheem Yacoub, MD, Ronald Hoffman, MD, John Mascarenhas, MD and Douglas Tremblay, MD

538 Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial
Time: 5:15 PM
Program: Oral and Poster Abstracts
Session: 637. Myelodysplastic Syndromes – Clinical and Epidemiological: Treatment of HIgh Risk and Relapsed/Refractory Myelodysplastic Syndrome
Mrinal M. Patnaik, MBBS, Haris Ali, MD, Eunice S. Wang, MD, Abdulraheem Yacoub, MD, Vikas Gupta, MD, FRCP, FRCPath, Sangmin Lee, MD, Gary J. Schiller, MD, James M. Foran, MD8, Ayalew Tefferi, MD, Christopher L Brooks, PhD, Guillermo Garcia-Manero, MD, Tariq I. Mughal, MD, FRCP and Naveen Pemmaraju, MD

2740 SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II
James E Hoffman, MD, Brea Lipe, MD, Jason Melear, MD, Michaela Liedtke, MD, Mark A. Schroeder, MD, Ruben Niesvizky, MD, Michael H. Tomasson, MD, Christopher A. Yasenchak, MD, Damian J. Green, MD, Hong Li, Yinghui Wang, MS, Phoenix Ho, MD and Al-Ola Abdallah, MD

408 Co-Expression of an shRNA Targeting MICA/Micb Improves the Clinical Activity of a NKG2D-Based CAR T in Patients with Relapsed / Refractory AML/MDS
Time: 10:45 AM
Program: Oral and Poster Abstracts
Session: 703. Cellular Immunotherapies: Basic and Translational II
Dries Deeren, MD, Johan A. Maertens, MD, PhD, Tara L. Lin, MD, Yves Beguin, MD, PhD, Erik Alcantar-Orozco, MD, Marie-Sophie Dheur, PhD, PharmD, Eytan Breman, Nathalie Braun, Caroline Lonez, PhD, David Gilham, PhD, Anne Flament, MD and Frédéric F. Lehmann, MD

2823 Safety and Cost Effectiveness of Chimeric Antigen Receptor T Cell Therapy in the Outpatient Setting
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Clinical: Poster II
Moazzam Shahzad, MD, Muhammad Salman Faisal, MD, Ernie Shippey, Ali Hussain, MD, Clint Divine, MBA, MSM, Zahra Mahmoudjafari, PhD, Allison Appenfeller, Muhammad Umair Mushtaq, MD, Leyla Shune, MD, Joseph P. McGuirk, DO and Nausheen Ahmed, MBBS

2843 Outcomes of Aggressive B Cell Lymphoma Patients with No Evidence of Measurable Disease at the Time of CD19 Chimeric Antigen Receptor T Cell Therapy: The Experience from the CAR T Cell Consortium
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 704. Cellular Immunotherapies: Clinical: Poster II
Kitsada Wudhikarn, MD, Ana Alarcon Tomas, Jamie Brower, MS, Veronika Bachanova, MD, PhD, Richard T. Maziarz, MD, Joseph P. McGuirk, DO, Loretta Nastoupil, MD, David L. Porter, MD, Peter A. Riedell, MD and Miguel-Angel Perales, MD

2863 Outcomes with Mismatched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation Following Reduced Intensity Conditioning: A Systematic Review and Meta-Analysis
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster II
Moazzam Shahzad, MD, Sibgha Gull Chaudhary, MD, Ezza Tariq, MBBS, Naira Fatima, MBBS, Muhammad Arslan, MD, Muhammad Usman Zafar, MD, Amna Y Shah, MD, Mamoon Ahmed, Iqra Anwar, MBBS, Nausheen Ahmed, MBBS, Leyla Shune, MD, Ramesh Balusu, PhD, Peiman Hematti, MD, Joseph P. McGuirk, DO and Muhammad Umair Mushtaq, MD

2922 Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative Study
Time: 6 - 8 PM
Program: Oral and Poster Abstracts
Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II
Michael T. Byrne, DO, Tony J Kurian, M2, Dilan A Patel, MD, Roni Tamari, MD, Sanghee Hong, MD, Haitham Abdelhakim, MD, Victoria Klein, Patricio Rojas, MD, Raksha Madhavan, MD, Andrew Kent, MD, PhD, Aaron C. Logan, MD, PhD, Catherine J. Lee, MD, Muhammad Husnain, MD, Benjamin M Manning, MD, PhD, Nicholas P. Tschernia, MD, Ajoy L. Dias, MD, Daniel Margalski, DO, Benjamin Goldenson, MD, PhD, Nathalie Byrne, APRN, Heidi Chen, PhD, Kseniya Petrova-Drus, MD, PhD, Salyka M. Sengsayadeth, MD, Aaron M Goodman, Dianna S. Howard, MD, William A. Wood, MD, MPH, Saar Gill, MD, PhD, Antonio M. Jimenez, MD, MSc, Jonathan A. Gutman, MD, Lohith Gowda, MD, Leland Metheny III, MD, Bhavana Bhatnagar, DO, Betty K. Hamilton, MD, Asmita Mishra, MD and Michael R. Savona, MD

Wednesday, December 8
GS2-07. Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER)
Kalinsky KM, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LA, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga J-Y, Bermejo B, Ramos-Vasquez M, Jung KH, Ferrero J-M, Schott A, Shak S, Sharma P, Lew D, Miao J, Tripathy D, Pusztai L, Hortobagyi G.

BASIC SCIENCE FORUM – Targeting Nuclear Steroid Receptors - PR
Christy R. Hagan, PhD

Poster Session 1
P1-09-03. Omega-3 polyunsaturated fatty acid supplementation shifts the gut and breast microbiome to influence inflammation
Cook KL, Wilson AS, Soto-Pantoja DR, Kimler BF, Umar S, Fabian CJ. 

P1-10-04.  AGR2, an estrogen response gene associated with tamoxifen resistance, is modulated by acolbifene in premenopausal women at high risk for development of breast cancer
Fabian CJ, Phillips TA, Kimler BF

Poster Session 2
P2-01-05.  Impact of post-treatment ctDNA and residual cancer burden (RCB) on outcomes in patients with triple-negative breast cancer (TNBC) and residual disease
Sharma P, Stecklein SR, Kimler BF, Yoder R, Schwensen K, Staley JM, Khan QJ, O'Dea AP, Nye LE, Elia M, Heldstab J, Home T, Hyter S, Isakova K, Pathak HB, Godwin AK.

P2-10-02.  Random periareolar fine-needle aspiration (RPFNA) cell number, prior precancerous breast disease and subsequent uptake of a prevention intervention predict short-term breast cancer risk
Hensing WL, Fabian CJ, Zalles CM, Sharma P, Kreutzjans AL, Powers KR, Chollet-Hilton L, Kimler BF.

P2-11-17.  Feasibility of microbiome analysis from random periareolar fine needle aspiration in premenopausal women at increased risk for breast cancer
Nye LE, Klemp JR, Powers KR, O'Dea AP, Kreutzjans AL, Metheny T, Phillips TA, Carlson SE, Kimler BF, Fabian CJ.

P2-11-21.  Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model
Hughes E, Bernhisel R, Pederson H, Probst B, Simmons T, Wagner S, Judkins T, Rosenthal E, Roa B, Domchek SM, Eng C, Garber J, Gary M, Gordon OK, Klemp J, Mukherjee S, Offit K, Olopade F, Vijai J, Weitzel J, Whitworth P, Yehia L, Kurian A, Robson M, Slavin TP, Gutin A, Lanchbury JS.

P2-13-34.  A phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer
Rooney A, Sharma P, O'Dea AP, Nye L, Elia M, He J, Fabian C, Khan Q.

Thursday, December 9

Spotlight Poster Discussion 8 - HER2 Positive Breast Cancer 
Optimizing use of HER2 therapies in metastatic HER2+ breast cancer and other subtypes
Priyanka Sharma, MD

Poster Session 3
P3-17-03.  Raising the level of cancer care around the world: The feasibility and perceived benefit of a virtual breast tumor board
Dempsey N, Chiec L, Lodder M, Shonkwiler E, Haines K, Mahtani R, Gradishar W, Buchholz T, O'Dea A, Wolmark N, Hurvitz S, O'Shaughnessy J, Jochelson M, Butler R, Mamounas E, Vicini F, Pegram M, Shah C, King T, O'Regan R, Morrow M, Jahanzeb M. Lynn

Poster Session 4 
P4-01-16.  Overcome chemoresistance of triple-negative breast cancer by inhibiting the RNA-binding protein HuR
Wei L, Zhang Q, Zhong C, Aubé J, Welch DR, Wu X, Xu L.

P4-04-07.  Progesterone promotes immunomodulation and tumor development in the murine mammary gland
Werner LR, Gibson KA, Goodman ML, Helm DE, Walter KR, Holloran SM, Trinca GM, Hastings RC, Yang HH, Hu Y, Wei J, Lei G, Yang X-Y, Madan R, Molinolo AA, Markiewicz MA, Chalise P, Axelrod ML, Balko JM, Hunter KW, Hartman ZC, Lange CA, Hagan CR.

P4-10-03.  Immunogenicity of SARS-CoV-2 vaccination in subjects on active treatment for breast cancer
Bivona C, Li K, Sharma P, He J, Martin G, Godwin AK, Rooney A, Williamson S, Doolittle G, Sun W, Kimler BF, O'Dea AP, Nye LE, McGuirk JP, Pessetto Z, Haney LH, Balmaceda N, Mitchell L, Finke K, Nelson M, Pal Mudaranthakam D, Streeter N, Lafaver S, Heldstab J, Khan QJ.

Spotlight Poster Discussion
PD9-06.  Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score® assay in node-positive postmenopausal breast cancer: Results from an analysis in the SWOG S8814 trial
Speers CW, Symmans WF, Barlow WE, Trevarton A, The S, Du L, Rae JM, Shak S, Baehner FL, Sharma P, Pusztai L, Hortobagyi GN, Hayes DF, Albain KS, Godwin A, Thompson A.

Friday, December 10

GS4-02. Analysis of clinical outcomes and expression-based immune signatures by race in the I-SPY 2 trial
Kyalwazi B, Yau C, Olopade O, A. Chien J, Wallace A, Forero-Torres A, Pusztai L, Ellis E, Albain K, Blaes A, Haley B, Boughey J, Elias A, Clark A, Isaacs C, Nanda R, Han H, Yung R, Tripathy D, Edmiston K, Viscusi R, Northfelt D, Khan Q, Sanil A, Berry S, Asare S, Wilson A, Hirst G, Hylton N, Melisko M, Perlmutter J, Rugo H, Symmans F, van ‘t Veer L, Berry D, Esserman L.

Poster Session 5
P5-01-03.  Mouse-intraductal (MIND): An in vivo model for studying the underlying mechanisms of DCIS malignancy
Behbod F, Hong Y, Limback D, Elsarraj HS, Rastogi A, Harper H, Ricci M, Kaufman C, Redick M, Wedlock E, Zhang J, May L, Cusick T, Inciardi M, Gatewood J, Winblad O, Aripoli A, Huppe A, Balanoff C, Wagner J, Amin A, Larson KE, Ricci L, Tawfik O, Razek H, Meierotto RO, Madan R, Godwin AK, Thompson J, Hilsenbeck SG, Futreal A, Thompson A, Hwang ES, Fan F

P5-04-05.  Loss of REST in breast cancer promotes tumor progression through estrogen sensitization, MMP24 and CEMIP overexpression
Vargheese AM, Cloud AS, Gunewardena S, Shimak RM, Ganeshkumar S, Kumaraswamy E, Jensen RA, Chennathukuzhi VM. 

Case-Based Panel Session: Understanding and Managing Chronic Effects of the Cancer Experience.
Available via pre-broadcast on June 4, 2021
Panel chair: Sean Robinson Smith
Panelists: Judith Paice, Candace Henley, Jamie S. Myers.

Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract 7033: Outcomes with COVID-19 in hematopoietic stem cell transplant and cellular therapy patients.
Muhammad Umair Mushtaq, Mary Luder, Moazzam Shahzad, Nausheen Ahmed, Haitham Abdelhakim, Rajat Bansal, Ramesh Balusu, Sibgha Gull Chaudhary, Shaun DeJarnette, Clint Divine, Robert Kribs, Leyla Shune, Anurag K Singh, Sunil H. Abhyankar, Siddhartha Ganguly, Joseph McGuirk.

Session: Prevention, Risk Reduction, and Hereditary Cancer
Abstract 10580:  Point of care genetic testing in a breast cancer survivorship clinic.
Lori Ranallo, Lauren Elizabeth Nye, Mary Williams, Carol J. Fabian, Anne O'Dea, Jennifer R. Klemp.

Abstract 10502:  Ancestrally unbiased polygenic breast cancer (BC) risk assessment.
Elisha Hughes, Placede Tiemeny, Shannon Gallagher, Stephanie Meek, Charis Eng, Monique Gary, Ora Gordon, Jennifer R. Klemp, Olufunmilayo I. Olopade, Holly Jane Pederson, Jeffrey N. Weitzel, Pat W. Whitworth, Lamis Yehia, Susanne Wagner, Thomas Paul Slavin, Alexander Gutin, Jerry Lanchbury

Session: Health Services Research and Quality Improvement
Abstract 6552:  Effect of income on patient decision-making in localized prostate cancer.
Xinglei Shen, Ying Cao, Aaron J. Katz, Deborah Usinger, Sarah Walden, Ronald C. Chen

Abstract 6578:  Associations between patient knowledge of others' experiences and treatment choice in men with localized prostate cancer.
Aaron J. Katz, Ying Cao, Xinglei Shen, Deborah Usinger, Sarah Walden, Ronald C. Chen

Abstract 6556:  In-hospital outcomes of CAR T-cell therapy in United States in 2018: A nationwide analysis.
Manoj P. Rai, Prabhjot Singh Bedi, Anup Kasi, Kathan Mehta

Abstract 6519:  Racial and ethnic representation trends in United States oncology training programs.
Conner Lombardi, Jacob Lang, Rochell Issa, Oluchi Ukaegbu Oke, Krishna Reddy, Obi Ekwenna

Abstract 6509:  Mortality risk for patients undergoing cancer treatment who acquire SARS-CoV-2: ASCO registry.
Kathryn Finch Mileham, Suanna Steeby Bruinooge, Charu Aggarwal, Alicia L. Patrick, Christiana Davis, Daniel Mesenhowski, Alexander I. Spira, Eric J. Clayton, David Michael Waterhouse, Sue Moore, Abdul-Rahman Jazieh, Ronald C. Chen, Melinda Kaltenbaugh, Jen Hanley Williams, Richard L. Schilsky, Liz Garrett-Mayer

Abstract 6500:  Racial and ethnic disparities among patients with breast cancer and COVID-19.
Gayathri Nagaraj, Melissa Kate Accordino, Benjamin French, Nicole M. Kuderer, Gary H. Lyman, Daniel G. Stover, Victoria Susana Blinder, Andrew Lachlan Schmidt, Rebecca Arielle Shatsky, Punita Grover, Matthew Puc, Clara Hwang, Elizabeth Marie Wulff-Burchfield, Mark Andrew Lewis, Alvaro G. Menendez, Mehmet Asim Bilen, Jeremy Lyle Warner, Maryam B. Lustberg, Dimpy P Shah

Session: Developmental Therapeutics—Immunotherapy
Abstract TPS2678:  Combination of atezolizumab and pirfenidone in second-line and beyond NSCLC: A phase I/II study.
Takefumi Komiya, Jun Zhang, Prakash C. Neupane, Kathan Mehta, Chao Hui Huang

Abstract 2510:  Safety, pharmacokinetic and pharmacodynamic results from dose escalation of SAR439459, a TGFβ inhibitor, as monotherapy or in combination with cemiplimab in a phase 1/1b study.
Stephen K. Williamson, F. Stephen Hodi, Melissa Lynne Johnson, Minal A. Barve, Dejan Juric, Joaquina Celebre Baranda, Reva Elaine Schneider, Todd Michael Bauer, Tun Tun Lin, Rui Wang, Amele Amrate, Helene Guillemin-Paveau, Ryan J. Sullivan

Abstract 2534:  PSMA targeted armored chimeric antigen receptor (CAR) T-cells in patients with advanced mCRPC: A phase I experience.
Matthew H. Carabasi, Meredith McKean, Mark N. Stein, Michael Thomas Schweizer, Jason J. Luke, Vivek Narayan, Russell Kent Pachynski, Rahul Atul Parikh, Jingsong Zhang, Thomas J. Fountaine, Jamie Rosen, Pam Hufner, Whitney Gladney, Karen Chagin

Abstract 2536:  Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101.
Antonio Jimeno, Joaquina Celebre Baranda, Monica M. Mita, Michael S. Gordon, Matthew H. Taylor, Wade Thomas Iams, Filip Janku, Ursula A. Matulonis, Howard Bernstein, Scott Loughhead, Martin Kornacker, Ricardo F. Zwirtes, Oliver Rosen, Cathy Eng

Abstract TPS2661: Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).
Adam Jacob Schoenfeld, Mehmet Altan, Taofeek K. Owonikoko, Sandra P. D'Angelo, Brian H. Ladle, Jonathan Christopher Noujaim, Kai He, David A. Liebner, Adrian G. Sacher, John B. A. G. Haanen, Jeffrey Yachnin,Chao H. Huang, Brian Andrew Van Tine, Aisha N. Hasan, Thomas H. Faitg, Emily Butler, Aiman Shalabi, Steven Attia, Dejka M. Araujo

Session: Breast Cancer—Metastatic
Abstract 1076:  Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).
Priyanka Sharma, Vandana G Abramson, Anne O'Dea, Lauren Elizabeth Nye, Ingrid A. Mayer, Gregory James Crane, Manana Elia, Rachel Yoder, Joshua M Staley, Kelsey Schwensen, Karissa Finke, Jaimie Heldstab, Stephanie LaFaver, Micki Prager, Stephen K. Williamson, Milind Phadnis, Gregory A Reed, Bruce F. Kimler, Qamar J. Khan, Andrew K. Godwin

Abstract 1077:  Assessment of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC).
Joyce O'Shaughnessy, Kevin Punie, Mafalda Oliveira, Filipa Lynce, Sara M. Tolaney, Florence Dalenc, Priyanka Sharma, Michaela L. Tsai, Aditya Bardia, Javier Cortes, Michael A. Danso, Stephanie Henry, Alejandra T. Perez, Sara A. Hurvitz, Kevin Kalinsky, Quan Hong, Martin Sebastian Olivo, Loretta Itri, Hope S. Rugo

Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract TPS7058:  A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naïve myelofibrosis.
Abdulraheem Yacoub, Susan Erickson-Viitanen, Feng Zhou, Albert Assad

Abstract 7026:  Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML.
Vinod Pullarkat, Mark J. Levis, Gabriel N. Mannis, Stephen Anthony Strickland, Tara L. Lin, Stefan Faderl, Divya Chakravarthy, Vijayalakshmi Chandrasekaran, Ronald Cheung, Harry Paul Erba

Session: Gastrointestinal Cancer—Colorectal and Anal
Abstract 3357:  Impact of BRAF mutations on prognosis and immunotherapy response in microsatellite instability/mismatch repair deficient metastatic colorectal cancer: A systematic review and meta-analysis.
Robin Park, Laércio Lopes da Silva, Sunggon Lee, Anwaar Saeed

Abstract 3563:  Increased neutrophil infiltration and lower prevalence of tumor mutation burden and microsatellite instability are hallmarks of RAS mutant colorectal cancers.
Emil Lou, Yasmine Baca, Joanne Xiu, Andrew Nelson, Subbaya Subramanian, Mohamed E. Salem, Muhammad Shaalan Beg, Elisa Fontana, Maria Diab, Philip Agop Philip, Richard M. Goldberg, Ritu Pandey, Tobias Arkenau, Weijing Sun, Heinz-Josef Lenz, Anthony Frank Shields, Wafik S. El-Deiry, Wolfgang Michael Korn

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract 4091:  Relationship between Helicobacter pylori and development of hepatocellular carcinoma: A systematic review and meta-analysis.
Samragnyi Madala, Kira MacDougall, Balarama Krishna Surapaneni, Robin Park, Anup Kasi, Mohit Girotra

Abstract 4086:  Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202.
Ghassan K. Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed Moh'd Taiseer Al-Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David H. Gallinson, Adrian Gerard Murphy, Do-Youn Oh, Efrat Dotan, Daniel Catenacci, Eric Van Cutsem, Christine Francis Lihou, Huiling Zhen, Luis Féliz, Arndt Vogel

Abstract 4085: Treatment-related toxicity and improved outcomes with immune checkpoint inhibitors in patients with hepatocellular carcinoma.
Alessio Cortellini, Thomas Urban Marron, Pallavi Shruti Mishra-Kalyani, Yutao Gong, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, Abdul Rafeh Naqash, Uqba Khan, Ahmed Omar Kaseb, Yi-Hsiang Huang, Celina Ang, Julie A. Schneider, Anjana Pillai, Lorenza Rimassa, Richard Pazdur, Marc Robert Theoret, Steven Lemery, Lorraine Cheryl Pelosof, David James Pinato

Session: Sarcoma
Abstract TPS11578:  A phase 2 study of belinostat and SGI-110 (guadecitabine) for the treatment of unresectable and metastatic conventional chondrosarcoma.
Jay Oza, Shing Mirn Lee, Mia C. Weiss, Brittany L Siontis, Benjamin C. Powers, Warren Allen Chow, Wendy Magana, Tahir Sheikh, Richard Piekarz, Gary K. Schwartz, Matthew Ingham

Abstract 11523:  Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.
Michael J Wagner, Matthew Ingham, Corrie Painter, Rashmi Chugh, Jonathan C. Trent, Vivek Subbiah, Ali Raza Khaki, Lisa May Ling Tachiki, Elizabeth Trice Loggers, Chris Labaki, Rana R. McKay, Elizabeth A. Griffiths, Katherine Anne Thornton, Anup Kasi, Clara Hwang, James Lin Chen, Thorvardur Ragnar Halfdanarson, Daniel Y. Reuben, Cathleen Park, Elizabeth J. Davis

Session: Professional Development and Education Advances
Abstract 11020:  Gender disparities in National Institute of Health funding for hematologic malignancies, hematopoietic stem cell transplantation, and cellular therapeutics.
Raheel Sufian Siddiqui, Moazzam Shahzad, Mahrukh Majeed, Ali Hussain, Faryal Murtaza, Farhan Khalid, Ayesha Habib, Zobia Aijaz, Syeda Sadia Bukhari, Iqra Anwar, Sehar Altaf, Faiz Anwer, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Siddhartha Ganguly, Sunil H. Abhyankar, Joseph McGuirk, Faisal Khosa, Muhammad Umair Mushtaq

Abstract 11043:  Representation trends in radiation oncology training programs in the United States.
Emilie Garcia, Jacob Lang, Oluchi Ukaegbu Oke, Krishna Reddy, Obi Ekwenna

Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Abstract TPS7570:  A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9–engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON).
Joseph McGuirk, Carlos R. Bachier, Michael Russell Bishop, P. Joy Ho, Hemant S. Murthy, Michael J. Dickinson, Joseph E. Maakaron, Charalambos Andreadis, Armin Ghobadi, Edmund K. Waller, Mark Daniel Benton, Susanna Suh, Huansheng Xu, Ewelina Morawa, Farrukh Tauseef Awan, Paul Shaughnessy, Constantine Si Lun Tam, Nicolaus Kroeger, Richard T. Maziarz

Session: Genitourinary Cancer—Kidney and Bladder
Abstract 4568:  Immune checkpoint inhibitors (ICI) in advanced sarcomatoid renal cell carcinoma (sRCC): A multicenter study.
Dharmesh Gopalakrishnan, Katharine Collier, Joseph J Park, Jacob P Zaemes, Elaine Tat Lam, Sabah Alaklabi, Ellen Jaeger, Rahul Atul Parikh, Pedro C. Barata, Eric Kauffman, Michael B. Atkins, Ajjai Shivaram Alva, Yuanquan Yang, Saby George

Abstract 4507:  A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.
Authors:  Sumanta K. Pal, Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh, Yung Lyou, Peng Wang, Rahul Atul Parikh, Benjamin A. Teply, Robert Dreicer, Hamid Emamekhoo, M. Dror Michaelson, Christopher J. Hoimes, Tian Zhang, Sandy Srinivas, William Y. Kim, Glenn Liu, Paul Henry Frankel, Yuijie Cui, Primo "Lucky" N. Lara

Abstract TPS4593:  A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801).
Authors:  Rana R. McKay, Heather Jacene, Pamela J. Atherton, Gabriela Perez Burbano, Archana Ajmera, Shiva Baghaie, Janet Koball, Tyler J. Zemla, Ronald C. Chen, Atish Dipankar Choudhury, Joshua Michael Lang, Suzanne Cole, Tareq Al Baghdadi, Young Kwok, Himisha Beltran, Daniel J. George, Michael J. Morris, Toni K. Choueiri

Session: Gynecologic Cancer
Abstract 5576:  Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.
Filip Janku, Erika P. Hamilton, Cara Amanda Mathews, Christina Chu, Jennifer Robinson Diamond, John L. Hays, Rebecca Christian Arend, Massimo Cristofanilli, Andrea Jewell, William Reichmann, Keisuke Kuida, Haroun Achour, Rodrigo Ruiz-Soto, Debra L. Richardson

Session: Genitourinary Cancer—Prostate, Testicular, and Penile
Abstract 5071:  The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.
Andrew J. Armstrong, Taro Iguchi, Arun Azad, Arnauld Villers, Boris Alekseev, Daniel P. Petrylak, Russell Zelig Szmulewitz, Antonio Alcaraz, Neal D. Shore, Jeffrey Holzbeierlein, Francisco Gomez-Veiga, Brad Rosbrook, Fabian Zohren, Gabriel P. Haas, Georgia Gourgioti, Nader N. El-Chaar, Arnulf Stenzl
  
Session: Symptoms and Survivorship
Abstract 12035:  Code status and outcomes in patients with cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) registry analysis.
Elizabeth Trice Loggers,Elizabeth Marie Wulff-Burchfield, Ishwaria Mohan Subbiah, Ali Raza Khaki, Pamela Egan, Dimitrios Farmakiotis, Hardeep Phull, Elizabeth Nakasone, Chris Labaki, Peter Paul Yu, Monika Joshi, Elizabeth A. Griffiths, Trisha Michel Wise-Draper, Chinmay Jani, Astha Thakkar, Matthew Puc, Clara Hwang, Blanche H. Mavromatis, Dimpy P Shah, Jeremy Lyle Warner

Session: Melanoma/Skin Cancers
Abstract 9515:  Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.
Omid Hamid, Ding Wang, Tae Min Kim, Sang-We Kim, Nehal J. Lakhani, Melissa Lynne Johnson, Roman Groisberg, Kyriakos P. Papadopoulos, John M. Kaczmar, Mark R. Middleton, Alexander I. Spira, Stephen K. Williamson, Guilherme Rabinowits, Rodolfo Gutierrez, Meredith McKean, Shuquan Chen, James Cassidy, Jayakumar Mani, Tasha Nicholle Sims, Glenn Kroog

Session: Biomarker-Driven Approaches for the Treatment of Gastrointestinal Cancers
Abstract 4010:  FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).
Daniel V.T. Catenacci, Yoon-Koo Kang, Anwaar Saeed, Kensei Yamaguchi, Shukui Qin, Keun-Wook Lee, In-Ho Kim, Sang Cheul Oh, Jin Li, Haci M. Turk, Alexandra Carolina Teixeira, Christophe Borg, Erika Hitre, Anghel Adrian Udrea, Giovanni Gerardo Cardellino, Raquel Guardeno, Siddhartha Mitra, Yingsi Yang, Peter C. Enzinger, Zev A. Wainberg

Session: Pediatric Oncology
Abstract 10051:  Standardization of fertility preservation discussion amongst pediatric oncology and bone marrow transplant patients.
Chandni Dargan, Sarah Mc Dermott, Shelby Chesbro, Joy M. Fulbright

Session: Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract e16194:  Efficacy of immunotherapy in hepatocholangiocarcinoma (HCC-CC): Proof of concept.
Osama Diab, Maloree Khan, Saqib Abbasi, Anwaar Saeed, Anup Kasi, Joaquina Celebre Baranda, Weijing Sun, Raed Moh'd Taiseer Al-Rajabi

Abstract e16273:  Early detection of pancreatic cancers by novel nanobiosensor-based protease biomarkers using hierarchical decision structure.
Anup Kasi, Weijing Sun, Sumia Ehsan, Jose Covarrubias, Kayla Eschliman, Raul Neri, Deepesh Agarwal, Obdulia Covarrubias Zambrano, Stefan H Bossmann, Bala Natarajan

Session: Publication Only: Gastrointestinal Cancer—Colorectal and Anal
Abstract e15613:  A novel outpatient regimen in management of fluoropyrimidine-induced cardiotoxicity.
Anup Kasi, Pramod Gaudel, Joseph Bennett, Raed Moh'd Taiseer Al-Rajabi, Anwaar Saeed, Joaquina Celebre Baranda, Weijing Sun, Charles B. Porter

Session: Publication Only: Health Services Research and Quality Improvement
Abstract e18578:  Prognostic impact of obesity in cancer patients with COVID-19 infection: A systematic review and meta-analysis.
Robin Park, Elizabeth Marie Wulff-Burchfield,Kathan Mehta,Weijing Sun,Anup Kasi

Abstract e18562:  Is chimeric antigen receptor T cell (CART) a destination procedure? Lower socioeconomic class who live farther from center have less access to CART.
Nausheen Ahmed, Ernie Shippey, Crissy Kus, Allison Appenfeller, Marc Steven Hoffmann, Aung M. Tun, Siddhartha Ganguly,Leyla Shune, Clint Devine, Rajat Bansal, Sunil H. Abhyankar, Muhammad Umair Mushtaq, Joseph McGuirk

Abstract e18611:  Outcomes with COVID-19 in patients with hematopoietic stem cell transplant and cellular therapy: A systemic review and meta-analysis.
Sibgha Gull Chaudhary, Muhammad Usman Zafar, Maha Awaiz Hassan, Moazzam Shahzad, Ali Hussain, Fatima Ali, Yumna Riaz, Fatima Khalid, Sharad Khurana, Ramesh Balusu, Nausheen Ahmed, Anurag K Singh, Faiz Anwer, Sunil H. Abhyankar,Joseph McGuirk, Muhammad Umair Mushtaq

Session: Publication Only: Care Delivery and Regulatory Policy
Abstract e13615:  Telehealth to increase access to transplant survivorship care for allogeneic stem cell transplant recipients regardless of distance to transplant center or neighborhood income.
Nausheen Ahmed, Sarah Fitzmaurice, Cherie Morey, Tania Torres, Darla Beckman, Siddhartha Ganguly, Rajat Bansal, Liza Rodriguez, Haitham Abdelhakim, Anurag K Singh,Sunil H. Abhyankar, Leyla Shune, Robert Kribs, Clint Devine, Jennifer Hanses, Muhammad Umair Mushtaq, Joseph McGuirk

Session: Publication Only: Lung Cancer—Non-Small Cell Metastatic
Abstract e21024:  Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.
Justin Chau, Meeta Yadav, Ben Liu, Muhammad Furqan, Qun Dai, Shailesh Shahi, Arnav Gupta, Keri Nace Mercer, Evan Eastman, Taher Abu Hejleh, Carlos Hou Fai Chan, George J. Weiner, Catherine Cherwin, Sonny T.M. Lee, Cuncong Zhong, Ashutosh Mangalam, Jun Zhang
  
Session: Publication Only: Genitourinary Cancer—Prostate, Testicular, and Penile
Abstract e17012:  Nationwide trends in in-patient chemotherapy hospitalizations, cost, and mortality for patients with testicular carcinoma.
Saqib Abbasi, Elizabeth Marie Wulff-Burchfield,Rahul Atul Parikh

Abstract e17020:  A phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE): Results of the phase 1 study.
Rana R. McKay, Wanling Xie, Archana Ajmera, Biren Saraiya, Mamta Parikh, Edmund Folefac, Adam C. Olson, Atish Dipankar Choudhury, David Johnson Einstein, Elisabeth I. Heath, Rahul Atul Parikh, Charles Kunos, S. Percy Ivy, Geoffrey Shapiro, Razelle Kurzrock

Session: Publication Only: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Abstract e19537:  Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.
Ulrich Jäger, Nina Worel, Joseph McGuirk, Peter A. Riedell, Isabelle Fleury, Peter Borchmann, Yan Du, Ahmed M. Abdelhady, Xia Han, Marcela Martinez-Prieto, Edmund K. Waller

Session: Publication Only: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract e19014:  Outcomes with preemptive donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndromes: A systematic review and meta-analysis.
Syed Ather Hussain, Atif N khan, VENKATA S THAMMINENI, Muhammad Nauman Riaz, Moazzam Shahzad, Priyanjali Pulipati, Fatima Khalid, Zahoor Ahmed, Iqra Anwar, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Sharad Khurana, Faiz Anwer, Muhammad Umair Mushtaq

Abstract e19002:  MRD assessment using NGS in patients with acute myeloid leukemia undergoing hematopoietic stem cell transplantation: Meta-analysis.
Osama Mosalem, Mahmoud Abdelsamia, Haitham Abdelhakim

Session: Publication Only: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract e19035:  Outcomes with venetoclax in myelodysplastic syndromes: A systematic review.
Razwana Khanam, Moazzam Shahzad, Pranali Santhoshini Pachika, Zahoor Ahmed, Fatima Ali, Adeel Masood, Zunairah Shah, Asmi Chattaraj, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Sharad Khurana, Faiz Anwer, Sunil H. Abhyankar,Joseph P McGuirk, Muhammad Umair Mushtaq

Abstract e19025: Acute polymyositis presenting as chronic graft-versus-host disease: A systemic review.
Abdul Basit, Moazzam Shahzad, Sibgha Gull Chaudhary, Fatima Khalid, Nausheen Ahmed, Sharad Khurana, Siddhartha Ganguly,Sunil H. Abhyankar, Joseph McGuirk, Muhammad Umair Mushtaq

Abstract e19012: Outcomes with CD34 stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation for hematologic malignancies: A systemic review and meta-analysis.
Moazzam Shahzad, Iqra Anwar, Raheel Sufian Siddiqui, Tehniat Faraz Ahmed, Mahrukh Majeed, Maha Awaiz Hassan, Zahoor Ahmed, Karun Neupane, Tayyaba Ali, Muhammad Salman Faisal, Masooma Naseem, Sibgha Gull Chaudhary, Ramesh Balusu, Nausheen Ahmed, Anurag K Singh,Sunil H. Abhyankar,Joseph McGuirk, Faiz Anwer, Muhammad Umair Mushtaq

Wednesday, December 9

Special Poster Discussion 2
8 am
Emerging from COVID-19 pandemic: Provider perspective on use of neoadjuvant endocrine therapy (NET) in early stage hormone receptor positive breast cancer
Park KU, Gregory ME, Lustberg MB, Bazan JG, Shen c, Rosenberg SM, Blinder VS, Sharma P, Pusztai L, Partridge AH, Thompson A.

Poster Session 2
8 am
PS2-04: Evaluating serum thymidine kinase 1 in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG S0226 trial.  
Paoletti C, Barlow WE, Bergqvist M, Mehta RS, Gralow JR, Hortobagyi GN, Albain KS, Pusztai L, Sharma P, Godwin AK, Thompson AM, Hayes DF, Rae J. 

Poster Session 6
8 am
PS6-04: Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2 negative breast cancer.
Yoder R, Kimler BF, Staley JM, Schwensen K, Wang YY, Finke K, O'Dea A, Nye L, Elia M, Crane G, McKittrick R, Pluenneke R, Madhusudhana S, Beck L, Rodriguez R, Shrestha A, Corum L, Marsico M, Godwin AK, Khan Q, Sharma P. 

Poster Session 7
8 am
PS7-44: Energetics and LifestyLe In InheritEd Syndromes (ELLIE'S Study).  
Nye LE, Cruz K, Friedman S, Rose D, Befort C, Sullivan DK, Hamilton-Reeves JM, Harlan-Williams LM, Behbod F, Wick J, Irwin M, Klemp J. 

Poster Session 11
8 am
PS11-10: A Phase 1b/2 Study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations.  
Aftimos P, Oliveira M, Punie K, Boni V, Hamilton E, Gucalp A, Shah P, Mina L, Sharma P, Bauman L, Campeau E, Attwell S, Snyder M, Norek K, Czibere A, Yu Y, Silverman MH, Lakhotia S, Domchek S, Litton J, Robson M. 

Poster Session 13
8 am
PS13-16: Pharmacokinetic Evaluation of an Oral Paclitaxel DHP107 (Liporaxel®) in Patients with Recurrent or Metastatic Breast Cancer (MBC): Phase II study (OPERA, NCT03326102).
Rugo HS, Pluard TJ, Sharma P, Melisko M, Al-Jazayrly G, Vidula N, Ji Y, Weng D, Lim H-S, Yoon KE, Cho HJ. 

Thursday, December 10
10 am
GS3-05.  Classification of triple negative breast cancer (TNBC) by DNA Damage Immune Response (DDIR) signature and Homologous Recombination Deficiency (HRD) status: Analysis of SWOG S9313 adjuvant trial. Stecklein SR, Barlow W, Pusztai L, Timms K, Kennedy R, Badve S, Gökmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi GN, Godwin AK, Thompson A, Hayes D, Sharma P. 

10:15 am
GS3-06.  Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Hurvitz SA, Tolaney SM, Punie K, Loirat D, Oliveira M, Kalinsky K, Zelnak A, Aftimos P, Dalenc F, Sardesai S, Hamiltion E, Sharma P, Recalde S, Gil EC, Traina T, O'Shaughnessy J, Cortés J, Tsai M, Vahdat L, Diéras V, Carey L, Rugo HS, Goldenberg DM, Hong Q, Olivo M, Itri LM, Bardia A. 

Panel Discussion
11:35 am - 12 pm    
De-escalation trials: What makes sense, what is useless and what's crazy
Moderator: Eric Winer 
Panelists:Lisa Carey, Liz Garrett-Mayer, Tari A. King, Priyanka Sharma, Sara M. Tolaney, Julia R. White

Spotlight Poster Discussion Session 5
2:15 - 3:30 pm
Mouse-intraductal (MIND): the first in vivo model to recapitulate the full spectrum of human dcis pathology. Behbod F, Hong Y, Limback D, Elsarraj HS, Harper H, Haines H, Hansford H, Ricci M, Kaufman C, Xu M, Zhang J, May L, Cusick T, Inciardi M, Redick M, Gatewood J, Aripoli A, Huppe A, Winblad O, Balanoff C, Wagner J, Amin AL, Larson KE, Ricci L, Tawfik O, Razek H, Meierotto RO, Madan R, Godwin AK, Thompson J, Futreal A, Thompson A, Hwang S, Fan F, On behalf of the Grand Challenge PRECISION consortium. 

Friday, December 11
10:15 am
GS4-07. Assessing prognosis after neoadjuvant therapy: A comparison between anatomic ypAJCC staging, Residual Cancer Burden Class and Neo-Bioscore.
van der Noordaa MEM, Yau C, Shad S, Osdoit M, Steenbruggen TG, de Croze D, Hamy A-S, Lae M, Reyal F, Del Monte-Millán M, Martin M, Lopez Tarruella S, I-SPY 2 TRIAL Consortium, Boughey JC, Goetz M, Hoskin T, Gould R, Valero V, Sonke G, van Seijen M, Wesseling J, Bartlett J, Edge S, Kim M-O, Abraham J, Caldas C, Earl H, Provenzano E, Sammut S-J, Cameron D, Graham A, Hall P, MacKintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele A, Dunn J, Hiller L, Hayward L, Thomas J, Cole K, Pusztai L, van 't Veer L, Symmans F, Esserman L. 

Spotlight Poster Session 13
1 pm – 2:15 pm
Site of recurrence after neoadjuvant therapy: a multi-center pooled analysis.
Shad S, van der Noordaa M, Osdoit M, de Croze D, Hamy A-S, Lae M, Reyal F, Martin M, Del Monte-Millán M, López-Tarruella S, I-SPY 2 TRIAL Consortium, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Sonke G, Steenbruggen TG, van Seijen M, Wesseling J, Bartlett J, Edge S, Kim M-O, Abraham J, Caldas C, Earl H, Provenzano E, Sammut S-J, Cameron D, Graham A, Hall P, Mackintosh L, Fang F, Godwin AK, Schwensen K, Sharma P, DeMichele A, Dunn J, Hiller L, Hayward L, Thomas J, Cole K, Pusztai L, Van't Veer L, Symmans F, Esserman L, Yau C. 

Spotlight Poster Session 11
2:15 pm – 3:30 pm
Randomized trial of 12 months of omega-3 fatty acids vs placebo during a weight loss intervention in post-menopausal women at increased risk for breast cancer.
Fabian CJ, Befort CA, Sullivan DK, Carlson SE, Nydegger JL, Kreutzjans AL, Powers KR, Phillips TA, Metheny T, Zalles CM, Giles ED, Hursting SD, Kimler BF. 

Spotlight Poster Session 12
3:30 pm - 4:30 pm
Chronic Health Conditions and Quality of Life in Breast Cancer Survivorship
Jennifer Klemp, PhD, MPH, MA, Chair,

75: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Program: Oral Presentation
Saturday, December 5, 2020: 7:30 AM
Ryotaro Nakamura, M.D., Wael Saber, MD, MS, Michael J Martens, PhD, Alyssa Ramirez, Bart L. Scott, MD, Betul Oran, MD, MS, Eric Leifer, Ph.D., Roni Tamari, MD, Asmita Mishra, MD, Richard T. Maziarz, MD, Joseph P. McGuirk, DO, Peter Westervelt, MD, PhD, Sumithra Vasu, MD, MBBS, Mrinal M. Patnaik, MD, MBBS, Rammurti Kamble, MD, Stephen J. Forman, MD, Mikkael A. Sekeres, Frederick R. Appelbaum, MD, Adam M. Mendizabal, MS, Brent Logan, PhD, Mary M. Horowitz, MD, MS and Corey Cutler, MD, MPH, FRCPC

24: A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results  
Program: Oral Presentation
Saturday, December 5, 2020: 7:30 AM
Keith W. Pratz, MD, Mohamad Cherry, MD, MS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark Levis, MD, PhD, Tara Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD, PhD, Gary J. Schiller, MD, Jason E. Hill, PhD, Angela James, PhD, Qiaoyang Lu, MS and Ramon V. Tiu, MD

135: High Doses of Targeted Radiation with Anti-CD45 Iodine Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Program: Oral Presentation
Saturday, December 5, 2020: 9:30 AM
Boglarka Gyurkocza, MD, Rajneesh Nath, MD, Hannah Choe, MD, Stuart Seropian, MD, Patrick J. Stiff, MD, Sunil Abhyankar, MD, Edward Agura, MD, Mark Litzow, MD, Benjamin K. Tomlinson, MD, George L. Chen, MD, Parameswaran Hari, MD, MRCP, Johnnie Orozco, MD, Zaid S. Al-Kadhimi, MD, Camille Abboud, MD, Koen Van Besien, MD, PhD, Mitchell Sabloff, MSc, MD, FRCPC, Margarida Magalhaes Magalhaes-Silverman, James M. Foran, MD, Michael W. Schuster, MD, Partow Kebriaei, MD, Moshe Levy, MD, Hillard M Lazarus, MD, Sergio A. Giralt, MD, Qing Liang, PhD, Mark S. Berger, MD, Vijay Reddy, MD, PhD and John M. Pagel, MD PhD

111: Escalated Dosing Schedules of CC-486 Are Effective and Well Tolerated for Patients Experiencing First Acute Myeloid Leukemia (AML) Relapse: Results from the Phase III QUAZAR AML-001 Maintenance Trial
Program: Oral Presentation
Saturday, December 5, 2020: 9:30 AM
Hartmut Döhner, Andrew H Wei, MBBS, PhD, Pau Montesinos, MD, PhD, Hervé Dombret, MD, Farhad Ravandi, MBBS, Hamid Sayar, MD, MSc, Kimmo Porkka, Irwindeep Sandhu, MD, Francesco Passamonti, Fabrizio Pane, MD, Tadeusz Robak, MD PhD, José F. Falantes, Andre C. Schuh, Gert Ossenkoppele, MD, PhD, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD and Gail J. Roboz, MD

214: Health-Related Quality of Life with CC-486 in Patients with Acute Myeloid Leukemia (AML) in First Remission Following Induction Chemotherapy (IC): Results from the Phase III QUAZAR AML-001 Maintenance Trial
Program: Oral Presentation
Saturday, December 5, 2020: 12:15 PM
Gail J. Roboz, MD, Hartmut Döhner, Christopher Pocock, MBBS, Hervé Dombret, MD, Farhad Ravandi, MBBS, Jun Ho Jang, MD, PhD, Dominik Selleslag, MD, Jiří Mayer, Uwe M. Martens, MD, Jane L. Liesveld, MD, Teresa Bernal del Castillo, MD, PhD, Ming-Chung Wang, MD, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, Julia Braverman, PhD, Salem Abi Nehme, PhD, C.L. Beach, PharmD and Andrew H Wei, MBBS, PhD

301: Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era
Program: Oral Presentation
Saturday, December 5, 2020: 3:15 PM
Dawn Maze, MD, FRCPC, MSc, Murat O. Arcasoy, MD, Ryan Henrie, MD, BSc, Sonia Cerquozzi, MD, Rammurti Kamble, MD, Samer Al Hadidi, MD, MSc, FACP, Abdulraheem Yacoub, MD, Mahmoud Elsawy, MB, Shireen Sirhan, MD, Anurag K. Singh, MD, Elliot Smith, BSc, Curtis Marcoux, MD MSc, Dietrich Werner, MD, FACP, FRCP, Wenda Greer, PhD, Auro Viswabandya, MD, Andrew Daly, MD, Hassan Sibai, MBBS, Caroline J McNamara, MBBS, Wei Xu, PhD, Katherine Lajkosz, Lynda Foltz, MD, FRCPC and Vikas Gupta, MD, FRCP, FRCPath

1596: Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Hematological Malignancies: Insights from the National Inpatient Sample
Program: Poster Presentation
Saturday, December 5, 2020
Ghulam Rehman Mohyuddin, MD, Kellen Gil, Brian McClune, Nausheen Ahmed, Al-Ola Abdallah, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Leyla Shune, MD and Saqib Abbasi

1582: Patterns and Growth of a Dedicated Pediatric Coagulation Consult Service in a Freestanding Children’s Hospital
Program: Poster Presentation
Saturday, December 5, 2020
Shannon L Carpenter, MD, Eryn Bilynsky, BSN, RN, CCRC, Dena Wideman, MSN, ANP, Kristina D'Agostino, MSN, APRN, Lauren E Amos, MD, Mukta Sharma, MD, MPH and Michael Silvey, DO

1091: Germline Variants Associated with Cancer Predisposition and Bone Marrow Failure Are Common in KMT2A-r Infant Acute Lymphoblastic Leukemia Patients
Program: Poster Presentation
Saturday, December 5, 2020
Sarah Mc Dermott, DO, Midhat S. Farooqi, MD, PhD, Azhar Saeed, MD, Byunggil Yoo, MS, Emily Farrow, PhD, CGC, Neil Miller, Patrick A. Brown, MD and Erin Guest, MD

934: Safety and Demonstrated Efficacy of Placenta-Derived Cell Therapy PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation: A Phase I International Multi-Center Study
Program: Poster Presentation
Saturday, December 5, 2020
Hillard Lazarus, Carolina Escobar, MD, Leland Metheny III, MD, Joseph P. McGuirk, DO, Tsila Zuckerman, MD, Mark Litzow, MD, Scott D. Rowley, MD, Racheli Ofir, PhD, Liran Shani, MD and Jacob M. Rowe, MB, BS

1123: Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance
Program: Poster Presentation
Saturday, December 5, 2020
Morton Coleman, MD, FACP, David Jacob Andorsky, MD, Abdulraheem Yacoub, MD, Jason M. Melear, MD, Suzanne R. Fanning, DO, Kathryn S. Kolibaba, MD, Frederick Lansigan, MD, Christopher M. Reynolds, MD, Grzegorz S. Nowakowski, MD, Mecide Gharibo, MD, Erin Ahn, MS, Ju Li, PhD, Mathias J. Rummel, MD, PhD and Jeff P Sharman, MD

1149: Efficacy and Safety of Tisagenlecleucel in Adult Patients with Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 Elara
Program: Poster Presentation
Saturday, December 5, 2020
Nathan H Fowler, MD, Michael Dickinson, DMed Sci, Martin Dreyling, MD, Joaquin Martinez-Lopez, MD, Arne Kolstad, MD, PhD, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Monalisa Ghosh, MD, Leslie L. Popplewell, MD, FACP, Julio C. Chavez, MD, Emmanuel Bachy, MD, PhD, Koji Kato, MD, PhD, Hideo Harigae, MD, PhD, Marie José Kersten, MD, PhD, Charalambos Andreadis, MD, Peter A. Riedell, MD, P. Joy Ho, MB.BS. (Hons), D.Phil (Oxon), FRACP, FRCPA, FFSc(RCPA), Jose Antonio Pérez-Simón, MD, Sarah J. Nagle, MD, Loretta J. Nastoupil, MD, Bastian von Tresckow, MD, Andres JM Ferreri, MD, Takanori Teshima, MD, Piers Patten, MD, PhD, Joseph P. McGuirk, DO, Andreas Petzer, MD, Fritz Offner, MD, PhD, Andreas Viardot, Professor Dr, Pier Luigi Zinzani, MD, Ram Malladi, MBBS(Lond), MRCP(UK), FRCPath, Lida Bubuteishvili Pacaud, MD, Alessandra Forcina, MD, Aiesha Zia, Stephen J. Schuster, MD and Catherine Thieblemont, MD, PhD

1154: Oral Nanatinostat (Nstat) and Valganciclovir (VGCV) in Patients with Recurrent Epstein-Barr Virus (EBV)-Positive Lymphomas: Initial Phase 2  
Program: Poster Presentation
Saturday, December 5, 2020
Pierluigi Porcu, MD, Bradley Haverkos, MD, MPH, MS, Onder Alpdogan, MD, Robert Baiocchi, MD, PhD, Jonathan E Brammer, MD, Tatyana A. Feldman, MD, Marcelo Capra, MD, PhD, Elizabeth A Brem, MD, Phillip Scheinberg, MD, Juliana Pereira, MD, PhD, Leyla Shune, MD, Afton Katkov, MSc, Robert McRae, Lisa Rojkjaer, MD, Ivor Royston, MD and Douglas V. Faller, MD, PhD

990: First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients  
Program: Poster Presentation
Saturday, December 5, 2020
Dries Deeren, MD, PhD, Johan A. Maertens, MD, PhD, Tara Lin, MD, Yves Beguin, MD, PhD, Benjamin Demoulin, PhD, Martina Fontaine, PhD, Panagiota A. Sotiropoulou, PhD, Erik Alcantar-Orozco, MD5, Eytan Breman, Marie-Sophie Dheur, PhD, PharmD, Nathalie Braun, Caroline Lonez, PhD, David E Gilham, PhD, Anne Flament, MD and Frédéric F. Lehmann, MD

036: CC-486 Improves Overall Survival (OS) and Relapse-Free Survival (RFS) for Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC), Regardless of Amount of Consolidation Received: Results from the Phase III QUAZAR AML-001 Maintenance Trial
Program: Poster Presentation
Saturday, December 5, 2020
Andrew Wei, MBBS, PhD, Gail J. Roboz, MD, Hervé Dombret, MD, Hartmut Döhner, Andre C. Schuh, Pau Montesinos, MD, PhD, Christopher Pocock, MBBS, Dominik Selleslag, MD, Sergey N. Bondarenko, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD and Farhad Ravandi, MBBS

1398: A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts
Program: Poster Presentation
Saturday, December 5, 2020
Omar Nadeem, MD, Clifton C Mo, MD, Jacob P. Laubach, MD, Giada Bianchi, MD, Robert Redd, Peter Barth, Trevor J. Bayliss, MD, Vaishali Sanchorawala, MD, Leyla Shune, MD, Alexandra Distaso, Virginia Dalton, MS, APRN, Adam S Sperling, MD, PhD, Laura Amweg, Mary McKenney, NP, Kathleen Colson, BS, BSN, RN, Ella L Millard, Isabella Hou, Alexandra Savell, BS, Kelly Masone, BA, Nikhil C. Munshi, MD, Irene M. Ghobrial, MD, Kenneth Anderson, MD and Paul G. Richardson, MD

1025: V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Patients with Previously Untreated Acute Myeloid Leukemia
Program: Poster Presentation
Saturday, December 5, 2020
Tara Lin, MD, Gabriel N. Mannis, MD, Harry P. Erba, Mark Levis, MD, PhD, Heng Zou, Stefan Faderl, Ronald S. Cheung and Vinod A. Pullarkat, MD

354: Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants.
Program: Oral Presentation
Sunday, December 6, 2020: 9:45 AM
Everett H Meyer, MD, PhD, Rasmus Hoeg, MD, Anna Moroz, MD, PhD, Bryan Xei, BS, Hsin-Hsu Wu, MD, Rahul Pawar, Kartoosh Heydari, MD, David B. Miklos, MD, PhD, Parveen Shiraz, MD, Lori S. Muffly, MD, MS, Sally Arai, MD, MS, Laura J. Johnston, MD, Robert Lowsky, MD, FRCP, Andrew R. Rezvani, MD, Judith A Shizuru, MD, PhD, Wen-Kai Weng, MD, PhD, Nathaniel Fernhoff, PhD, Gerhard Bauer, Arpita Gandhi, MD, MS, Amy Putnam, J. Scott Scott McClellan, MD, PhD, Bronwen E. Shaw, PhD, MRCP, FRCPath, Joseph P. McGuirk, DO, Mehrdad Abedi, MD and Robert S. Negrin, MD

388: Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG
Program: Oral Presentation
Sunday, December 6, 2020: 12:00 PM
Sara Zarnegar-Lumley, MD, Todd A. Alonzo, PhD, Megan Othus, PhD, Zhuoxin Sun, PhD, Rhonda E. Ries, MA, Yi-Cheng Wang, MS, Amanda R. Leonti, MS, Matthew A. Kutny, MD, Derek Stirewalt, MD, Jerald P. Radich, MD, Frederick R. Appelbaum, MD, Era L Pogosova-Agadjanyan, BS, Kristen Marie O'Dwyer, MD, Harry P. Erba, MD, PhD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD, Mark Litzow, MD, Ehab L. Atallah, MD, Selina M. Luger, MD, FRCPC, Ross L. Levine, MD, Todd M. Cooper, DO, Alan S. Gamis, MD, MPH, Richard Aplenc, MD, PhD, Anders E. Kolb, MD, Soheil Meshinchi, MD, PhD and Katherine Tarlock, MD

393: The Molecular Characteristics and Clinical Relevance of NUP98-Other Translocations in Pediatric Acute Myeloid Leukemia
Program: Oral Presentation
Sunday, December 6, 2020: 1:15 PM
Jenny L. Smith, MSc, MEd, Rhonda E. Ries, MA, Todd A. Alonzo, PhD, Fabiana Ostronoff, MD, Gertjan J.L. Kaspers, Prof. MD, PhD, Henrik Hasle, PhD, Christian M. Zwaan, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Todd M. Cooper, DO, Richard Aplenc, MD, PhD, Alan S. Gamis, MD, MPH, Edward A. Kolb, MD, Bianca F. Goemans, MD, PhD and Soheil Meshinchi, MD, PhD

479: Safety and Efficacy of Idasanutlin in Patients (pts) with Hydroxyurea (HU)-Resistant/Intolerant Polycythemia Vera (PV): Results of an International Phase II Study
Program: Oral Presentation
Sunday, December 6, 2020: 2:00 PM
John Mascarenhas, MD, Brian Higgins, Doreen Anders, Kate Burbury, MD, Tarec Christoffer El-Galaly, Aaron T. Gerds, MD, MS, Vikas Gupta, MD, FRCP, FRCPath, Bruno Kovic, Margherita Maffioli, MD, Ruben Mesa, MD, Jeanne M. Palmer, Md, Francesco Passamonti, MD, Alessandro Rambaldi, MD, David M Ross, MBBS, PhD, FRACP, FRCPA, Alessandro M. Vannucchi, MD and Abdulraheem Yacoub, MD

482: PTG-300 Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera Patients.  
Program: Oral Presentation
Sunday, December 6, 2020: 2:45 PM
Marina Kremyanskaya, Yelena Ginzburg, MD, Andrew T. Kuykendall, MD, Abdulraheem Yacoub, MD, Jay Yang, MD, Suneel K Gupta, PhD, Frank Valone, MD, Sarita Khanna, PhD, Srdan Verstovsek, MD, PhD and Ronald Hoffman, MD

468: Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)
Program: Oral Presentation
Sunday, December 6, 2020: 3:00 PM
Liora M. Schultz, MD, Christina Baggott, RN, PhD, Snehit Prabhu, PhD, Holly Pacenta, MD, Christine L Phillips, MD, Jenna Rossoff, MD, Heather Stefanski, MD, PhD, Julie-An Talano, MD, Amy Moskop, MD, Steven P. Margossian, MD, PhD, Michael R Verneris, MD, Gary Douglas Myers, MD, Nicole Karras, MD, Patrick A. Brown, MD, Muna Qayed, MD, MSc, Michelle Hermiston, MD, PhD, Prakash Satwani, MD, Christa Krupski, DO, MPH, Amy Keating, MD, Rachel Wilcox, Cara A Rabik, MD, PhD, Vanessa Fabrizio, MD, Michael Kunicki, Vasant Chinnabhandar, MD, A. Yasemin Goksenin, MD, PhD, MA, MPH, Kevin J. Curran, MD, Crystal L. Mackall, MD and Theodore W. Laetsch, MD

2039: Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era
Program: Poster Presentation
Sunday, December 6, 2020
Aung M Tun, MD, Raphael Mwangi, Brian K. Link, MD, Andrew L. Feldman, MD, Matthew J. Maurer, MS, Thomas E. Witzig, MD, Carrie A. Thompson, MD, Anne J. Novak, PhD, Jose C Villasboas, MD, Umar Farooq, MD, Sergei Syrbu, MD, PhD, James R. Cerhan, MD, PhD and Thomas M. Habermann, MD

1936: Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release
Program: Poster Presentation
Sunday, December 6, 2020
Jenna Rossoff, MD, Christina Baggott, RN, PhD, Snehit Prabhu, PhD, Holly Pacenta, MD, Christine L Phillips, MD, Heather Stefanski, MD, PhD, Julie-An Talano, MD, Amy Moskop, MD, Steven P. Margossian, MD, PhD, Michael R Verneris, MD, Gary Douglas Myers, MD, Nicole Karras, MD, Patrick A. Brown, MD, Muna Qayed, MD, MSc, Michelle Hermiston, MD, PhD, Prakash Satwani, MD, Christa Krupski, DO, MPH, Amy Keating, MD, Rachel Wilcox, Cara A Rabik, MD, PhD, Vanessa Fabrizio, MD, Michael Kunicki, Vasant Chinnabhandar, MD, A. Yasemin Goksenin, MD, PhD, MA, MPH, Kevin J. Curran, MD, Crystal L. Mackall, MD, Theodore W. Laetsch, MD and Liora M. Schultz, MD

2557: A Systematic Review and Network Meta-Analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide Refractory Multiple Myeloma.  
Program: Poster Presentation
Sunday, December 6, 2020
Ghulam Rehman Mohyuddin, Jill Hampton, Muhammad Aziz, Sadik Khuder, Ph.D, Saad Ullah Malik, MD, Brian McClune and Al-Ola Abdallah, MD

3260: First-in-Human Phase I Trial of Adoptive Immunotherapy with Ex Vivo Expanded and Activated Γδ T Cells Following Haploidentical Bone Marrow 
Program: Poster Presentation
Sunday, December 6, 2020
Lawrence S. Lamb Jr., PhD, Melissa Jo Beelen, Samantha Langford Youngblood, BS, Rupal Soder, PhD, Sunil Abhyankar, MD and Joseph P. McGuirk, DO

2285: Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data  
Program: Poster Presentation
Sunday, December 6, 2020
Shaji K. Kumar, MD, Al-Ola Abdallah, MD, Ashraf Z. Badros, MD, Betsy Laplant, MS, Binod Dhakal, MS, Melissa Alsina, MD, Rafat Abonour, MD, Cara A. Rosenbaum, MD, William I Bensinger, MD, Manisha Bhutani, MD, Andrzej Jakubowiak, MD, PhD, Erica Kim and Brian G.M. Durie, MD

2314: Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial
Program: Poster Presentation
Sunday, December 6, 2020
David S. Siegel, MD, Gary J. Schiller, MD, Christy J. Samaras, DO, Michael Sebag, MD, PhD, FRCPC, Jesus G. Berdeja, MD, Siddhartha Ganguly, MD, Jeffrey V. Matous, MD, Kevin W Song, MD, FRCPC, Christopher S. Seet, MD, PhD, Mirelis Acosta-Rivera, Michael Bar, Donald P. Quick, MD, Bertrand M. Anz III, MD, Gustavo A. Fonseca, MD, Donna E. Reece, MD, Kim Lee, Weiyuan Chung, Amit Agarwal, MD, PhD and Nizar Bahlis, MD

1946: Quality-Adjusted Time without Symptoms of Disease and Toxicity (Q-TWiST) Analysis of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed High-Risk/Secondary Acute Myeloid Leukemia (AML)
Program: Poster Presentation
Sunday, December 6, 2020
Jorge E. Cortes, MD, Tara Lin, MD, Geoffrey L Uy, MD, Robert J. Ryan, Stefan Faderl and Jeffrey E. Lancet, MD

1917: Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial
Program: Poster Presentation
Sunday, December 6, 2020
Farhad Ravandi, MBBS, Christopher Pocock, MBBS, Dominik Selleslag, MD, Pau Montesinos, MD, PhD, Hamid Sayar, MD, MSc, Maurizio Musso, MD, Angela Figuera Alvarez, Hana Safah, MD8, William Tse, MD, FACP, Sang Kyun Sohn, MD, PhD, Devendra Hiwase, MBBS, MD, FRACP, FRCPA, PhD, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD and Hervé Dombret, MD

1853: Targeting of Calbindin 1 (CALB1) Rescues Erythropoiesis in a Human Model of Diamond Blackfan Anemia: Implications for Novel Therapies
Program: Poster Presentation
Sunday, December 6, 2020
Nan of Wang, PhD, Corinne Marie Lavasseur, BA, Hongxia Yan, MS, Scott Younger, PhD, Bertil Glader, MD, PhD, Kathleen M. Sakamoto, MD, PhD, Lionel Blanc, PhD and Anupama Narla, MD

621: CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial
Program: Oral Presentation
Monday, December 7, 2020: 9:15 AM
Esther Natalie Oliva, MD, Suman Kambhampati, MD, Albert Oriol, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Qian Dong, DrPH, Clara Chen, Sandip Ranjan, MTech, Zephirin Kiendrebeogo, Msc, PMP and Thorsten Braun, MD, PhD

636: Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial
Program: Oral Presentation
Monday, December 7, 2020: 12:30 PM
Eytan M. Stein, MD, Ying Huang, MS, MA, Uma Borate, Maria R. Baer, M.D., Wendy Stock, MD, Tibor Kovacsovics, MD, William Blum, MD, Gary J. Schiller, MD, Rebecca L. Olin, MD, James M. Foran, MD, Mark Litzow, MD, Tara Lin, MD, Prapti Patel, MD, Matthew C Foster, MD, Michael Boyiadzis, MD, Robert H. Collins, MD, Jo-Anne Vergilio, M.D., Nyla A Heerema, PhD, Leonard Rosenberg, Ashley Owen Yocum, PhD, Timothy Chen, PhD, Franchesca Druggan, MSc, Sonja Marcus, MPH, Mona Stefanos, MBChB, Jordan Chervin, Abigail Shoben, Brian J. Druker, MD, Amy Burd, PhD, John C. Byrd, MD, Ross L. Levine, MD and Alice S. Mims, MD

692: CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial 
Program: Oral Presentation
Monday, December 7, 2020: 2:30 PM
Gail J. Roboz, MD, Farhad Ravandi, MBBS, Andrew H Wei, MBBS, PhD, Hervé Dombret, MD, Hartmut Döhner, Felicitas Thol, Maria Teresa Voso, MD, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Alberto Risueño, Daniel Lopes de Menezes, PhD and Gert Ossenkoppele, MD, PhD

747: Economic and Clinical Burden of Virus Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation 
Session Name: Health Services Research—Malignant Conditions (Lymphoid Disease) I
Program: Oral Presentation
Monday, December 7, 2020: 2:45 PM
Presenter: Joseph P. McGuirk, DO, The University of Kansas Cancer Center 

3267: A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC Derived TCR Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell
Program: Poster Presentation
Monday, December 7, 2020
Jae H. Park, MD, Nitin Jain, MD, Andy Chen, MD, PhD, Joseph P. McGuirk, DO, Monica Diaz, Bahram Valamehr, PhD, Yu-Waye Chu, MD and Januario E. Castro, MD

2887: CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells
Program: Poster Presentation
Monday, December 7, 2020
Diana R. Dunshee, Yumin Dai, Jessica C. Jang, Alberto Risueño, Danny V Jeyaraju, Patrick Hagner, PhD, Wendy L. See, Kyle MacBeth, Xiaomin Wang, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Anjan Thakurta and Daniel Lopes de Menezes, PhD

3346: Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients Enrolled in CPX-351-301, a Randomized Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk and/or Secondary AML
Program: Poster Presentation
Monday, December 7, 2020
Geoffrey L Uy, MD, Laura F. Newell, MD, Tara Lin, MD, Stuart L. Goldberg, Matthew J. Wieduwilt, MD, PhD, Robert J. Ryan, Stefan Faderl and Jeffrey E. Lancet, MD

4703 / 6 - Role of REST in the regulation of MMP24 and estrogen sensitivity in breast cancer

Aditya M. Vargheese, Ashley Cloud, Sumedha Gunewardena, Raeann Shimak, Easwari Kumaraswamy, Roy A. Jensen, Vargheese M. Chennathukuzhi.

6405 / 29 - Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting Notch signaling

Scott James Weir, Prasad Dandawate, Prabhu Ramamoorthy, Parthasarathy Ranjarajan, Robyn Wood, Amanda Brinker, Benjamin Woolbright, Mehmet Tanol, Tammy Ham, William McCulloch, Michael Dalton, Michael J. Baltezor, Roy A. Jensen, John A. Taylor III, Shrikant Anant.

5150 / 5 - MIF-2 in bladder cancer: potential therapeutic target

Ganeshkumar Rajendran, Benjamin L. Woolbright, Erika Abbott, Austin Martin, Katie Dennis, John Arthur Taylor III.

1120 / 2 - Randomized clinical trial of a flaxseed lignan in pre-menopausal women at high risk for development of breast cancer

Carol J. Fabian, Seema A. Khan, Judy E. Garber, William C. Dooley, Lisa D. Yee, Carola M. Zalles, Trina Metheny, Teresa A. Phillips, Jinxiang Hu, Brian K. Petroff, Stephen D. Hursting, Bruce F. Kimler.

1379 / 15 - Entinostat induces PARPi sensitivity across multiple ovarian cancer models

Vijayalaxmi G. Gupta, Shariska Petersen, Jeff Hirst, Katherine Roby, Harsh Pathak, Meghan Kusch, Andrew Wilson, Andrew Godwin, Dineo Khabele.

6176 / 16 - Preclinical analysis: BCN057 induces apoptosis in Kras mutant tumors

Andrew J. Norris, Payel Bhanja, Felipe Rodriguez Tirado, Andrew Hoover, Elizabeth M. Singer, William McBride, Subhrajit Saha.

4140 / 17 - Dissecting the structural basis for rational inhibitor design: Crystal and solution structures of human oncoprotein Musashi-2 N-terminal RNA recognition motif 1

Lan Lan, Minli Xing, Maithri Kashipathy, Justin Douglas, Philip Gao, Kevin Battaile, Robert Hanzlik, Scott Lovell, Liang Xu.

2662 / 10 - Mitochondrial genetics appear to alter immune cell development/trafficking

Thomas C. Beadnell, Amanda E. Brinker, Cori Fain, Carolyn J. Vivian, Danny R. Welch.

2026 / 4 - Outcomes in elderly patients with non-small-cell lung cancer receiving immune checkpoint inhibitor therapy: A real world experience

Jacob Ripp, Ghulam R. Mohyuddin, Mohammed Al-Jumayli, Chao Huang.

5417 / 19 - Genomic analysis of infant KMT2A-r acute lymphoblastic leukemia reveals weak association with underlying germline cancer predisposition

Azhar Saeed, Midhat Farooqi, Byunggil Yoo, Rumen Kostadinov, Emily Farrow, Neil Miller, Patrick Brown, Erin Guest.

1205 / 13 - Leveraging genome-wide methylation data to understand lung cancer risk in heavy smokers

Laurie Grieshober, Jincheng Shen, Stefan Graw, Matt J. Barnett, Mark D. Thornquist, Gary E. Goodman, Chu Chen, Devin C. Koestler, Carmen J. Marsit, Jennifer A. Doherty.

6474 / 8 - FAT1 and CASP8 co-mutations are associated with poor prognosis in HPV negative head and neck squamous cell carcinoma

Emrullah Yilmaz, David Lee, Andrew Cowan, Gregory Gan, Michelle Ozbun, Yan Guo.

784 / 21 - Effect of co-mutations and FLT3-ITD variant allele frequency (VAF) on response to quizartinib or salvage chemotherapy (SC) in relapsed/refractory (R/R) acute myeloid leukemia (AML)

Alexander E. Perl, Jorge E. Cortes, Siddhartha Ganguly, Samer K. Khaled, Alwin Krämer, Giovanni Martinelli, Nigel H. Russell, Ken C. N. Chang, Kazunobu Kato, Yuhu Yan, Li-An Xu, Sergey Korkhov, Tobias Günnel, Hiroyuki Sumi, Arnaud Lesegretain, Flora Berisha, Derek Mires, Aziz Benzohra, Takeshi Isoyama, Cedric Dos Santos, Mark J. Levis.

CT162 - The phase 1b PORTIA study: Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)

Ulrich Jaeger, Nina Worel, Joseph P. McGuirk, Peter A. Riedell, Isabelle Fleury, Peter Borchmann, Simon Newsome, Ahmed M. Abdelhady, Alessandra Forcina, Lida Bubuteishvili Pacaud, Edmund K. Waller.

LB-258 / 2 - Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis

Barbara Burtness, Danny Rischin, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto De Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Joy Ge, Ramona Swaby, Burak Gumuscu, Kevin Harrington.

1921 / 5 - TheDDB2 intronic variation rs830083 is a strong predictor of gemtuzumab ozogamicin response in AML patients: A calicheamicin pathway-directed analysis from the COG-AAML0531 trial

Vivek M. Shastri, Lata Chauhan, Todd A. Alonzo, Yi-Cheng Wang, Richard Aplenc, Betsy A. Hirsch, Alan S. Gamis, Soheil Meshinchi, Jatinder K. Lamba.

3417 - A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The small bowel tumor cohort

Young Kwang Chae, Megan Othus, Sandip Pravin Patel, Mark Zalupski, Anup Kasi, Maged Khalil, Aparna Kalyan, Blase Polite, Sarah Fenton, Sewan Gurung, Christine M. McLeod, Francis Giles, Helen X. Chen, Elad Sharon, Edward Mayerson, Melissa Plets, Christopher W. Ryan, Charles D. Blanke, Razelle Kurzrock.